This site is intended for healthcare professionals only

Asthma Guidance – part 1

The British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) published their British guideline for the management of asthma in September 2016. This was followed in November 2017 by the publication by NICE of Asthma: diagnosis, monitoring and chronic asthma management.

Discrepancies between the two guidelines have the potential to introduce uncertainty for clinicians and inconsistencies in the care of individual patients.

In November 2017, PCRS-UK released a briefing document, entitled Asthma guidelines, that (1) sets out their position and recommendations about the most practical approach to asthma diagnosis, monitoring and management for a primary care audience in the UK, based on its assessment of and taking account of the guidelines from BTS/SIGN and NICE; (2) comments on the differences between the BTS/SIGN asthma guideline and the NICE asthma guideline on diagnosing, monitoring and chronic management; and (3) confirms PCRS-UK’s response to the new NICE guideline.

Based on this briefing paper, PCRS-UK has now published consensus statement, written by DR Luke Daines (GP and Academic Fellow, University of Edinburgh), in conjunction with GP and nurse colleagues, covering asthma diagnosis, diagnosis in children, asthma management, add-on therapies and asthma monitoring.

The authors call for collaboration between NICE and BTS/SIGN in developing a single asthma guideline, a view further elaborated by Noel Baxter and Duncan Keeley in an article recently published in BMJ entitled ‘Conflicting asthma guidelines cause confusion in primary care’.

Asthma Guidance - part 1


Media partners


The Primary Care Respiratory Academy has been developed and is produced by Cogora, the publisher of Pulse, Nursing in Practice and Healthcare Leader working in partnership with PCRS-UK. All educational content for the website and roadshows has been initiated and produced by PCRS-UK/Cogora.

The Clinical Platform is funded by Circassia Pharmaceuticals.

GSK Logo

The Commissioning Platform is funded by GlaxoSmithKline.